The pro-tumor effect of CD200 expression is not mimicked by agonistic CD200R antibodies.
Animals
Antibodies
/ administration & dosage
Antigens, CD
/ genetics
Carcinoma, Lewis Lung
/ immunology
Cell Line, Tumor
Disease Progression
Female
Immunotherapy
Mammary Neoplasms, Experimental
/ immunology
Melanoma, Experimental
/ immunology
Membrane Glycoproteins
/ agonists
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Knockout
Myeloid Cells
/ immunology
Neoplasms, Experimental
/ immunology
Signal Transduction
/ immunology
Tumor Microenvironment
/ immunology
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
17
07
2018
accepted:
02
01
2019
entrez:
18
1
2019
pubmed:
18
1
2019
medline:
23
10
2019
Statut:
epublish
Résumé
Tumor-infiltrating immune cells can impact tumor growth and progression. The inhibitory CD200 receptor (CD200R) suppresses the activation of myeloid cells and lack of this pathway results in a reduction of tumor growth, conversely a tumorigenic effect of CD200R triggering was also described. Here we investigated the role of CD200R activation in syngeneic mouse tumor models. We showed that agonistic CD200R antibody reached tumors, but had no significant impact on tumor growth and minor effect on infiltration of immune myeloid cells. These effects were reproduced using two different anti-CD200R clones. In contrast, we showed that CD200-deficiency did decrease melanoma tumor burden. The presence of either endogenous or tumor-expressed CD200 restored the growth of metastatic melanoma foci. On the basis of these findings, we conclude that blockade of the endogenous ligand CD200 prevented the tumorigenic effect of CD200R-expressing myeloid cells in the tumor microenvironment, whereas agonistic anti-CD200R has no effect on tumor development.
Identifiants
pubmed: 30653571
doi: 10.1371/journal.pone.0210796
pii: PONE-D-18-21021
pmc: PMC6336379
doi:
Substances chimiques
Antibodies
0
Antigens, CD
0
CD200 receptor, mouse
0
Membrane Glycoproteins
0
antigens, CD200
UQ4V77A8VA
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0210796Déclaration de conflit d'intérêts
Involvement of one of the Bioceros BV does not alter authors’ adherence to PLOS ONE policies on sharing data and materials.
Références
Oncogene. 2012 Jun 14;31(24):2979-88
pubmed: 22020332
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
F1000Prime Rep. 2014 Mar 03;6:13
pubmed: 24669294
PLoS One. 2013 May 14;8(5):e63325
pubmed: 23691022
J Immunol. 2006 Jan 1;176(1):191-9
pubmed: 16365410
Cancer Res. 2010 Apr 1;70(7):2962-72
pubmed: 20332223
J Immunol. 2009 Aug 1;183(3):1990-6
pubmed: 19587022
Cell Host Microbe. 2010 Sep 16;8(3):236-47
pubmed: 20833375
J Virol. 2005 May;79(10):6052-67
pubmed: 15857991
J Immunol. 2004 Jun 15;172(12):7744-9
pubmed: 15187158
Curr Opin Immunol. 2012 Apr;24(2):233-8
pubmed: 22264927
Adv Immunol. 2014;121:191-211
pubmed: 24388216
Blood. 2006 Dec 15;108(13):4194-7
pubmed: 16946299
Science. 2000 Dec 1;290(5497):1768-71
pubmed: 11099416
Nat Immunol. 2008 Sep;9(9):1074-83
pubmed: 18660812
Cancer Immunol Res. 2018 Aug;6(8):930-940
pubmed: 30021725
Breast Cancer Res Treat. 2013 Nov;142(2):271-82
pubmed: 24166280
J Physiol Pharmacol. 2017 Aug;68(4):573-583
pubmed: 29151074
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
PLoS Pathog. 2012;8(5):e1002710
pubmed: 22615569
J Virol. 2004 Jul;78(14):7667-76
pubmed: 15220441
Leukemia. 2007 Mar;21(3):566-8
pubmed: 17252007
J Innate Immun. 2010;2(2):195-200
pubmed: 20375636
J Immunol. 2007 May 1;178(9):5595-605
pubmed: 17442942
PLoS One. 2012;7(2):e31442
pubmed: 22319630
Oncogene. 2015 Jul;34(29):3860-70
pubmed: 25263452
J Immunol. 2005 Aug 15;175(4):2469-74
pubmed: 16081818